Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

El.En.

Investor Presentation • Oct 21, 2015

4393_cp_2015-10-21_1546b8b4-38c2-4e81-886b-9cfc0352b565.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

COMPANY PRESENTATION

Oct. 21st , 2015

Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Summary

  • 1.LASERS AND LASER APPLICATIONS
  • 2.THE GLOBAL LASER MARKET
  • 3.EL.EN. GROUP
  • 4.H1 - 2015 FINANCIAL RESULTS
  • 5.2015 GUIDANCE
  • 6.EL.EN. STOCK, MULTIPLES & COMPARABLES

Lasers and Laser Applications

LASER

Light Amplification by Stimulated Emission of Radiation

MEDICALLASER Systems

INDUSTRIALLASER Systems

Medical Applications

Aesthetic Applications

Industrial Applications

The Global Laser Market

The MEDICAL Laser Market

k
C
A
G
2
0
1
3
2
0
1
8
M
R
t
a
r
e
-
k
M
t
t
a
r
e
s
e
g
m
e
n		 h
N
t
o
r
i
A
m
e
r
c
a		 E
u
r
o
p
e		 i
A
s
a		 i
L
t
a
n
i
A
m
e
r
c
a		 l
T
t
o
a
E
D
i
n
e
r
g
e
c
e
s
y
v		 6
9
%
,		 3
2
%
,		 1
5
3
%
,		 9
0
%
,		 7
8
%
,
k
i
j
i
S
R
t
n
e
u
v
e
n
a
o
n		 %
7
3
,		 %
5
8
,		 %
1
3
0
,		 %
1
1
8
,		 %
8
2
,
d
B
C
i
t
o
o
n
o
r
n
g
y
u		 1
1
3
%
,		 6
4
%
,		 1
8
3
%
,		 1
5
7
%
,		 1
2
4
%
,

Source: Medical Insight, Inc.

The INDUSTRIAL Laser Market

Global market and forecast for high power laser systems by application (by value)

l
B
V
y
a
u
e		 l
b
l
G
M
o
a
a		 (
k
i
l
E
U
R
M
t
r
e		 (
)
C
A
G
R
%
2
0
1
3		 2
0
1
6		 2
0
2
0		 2
0
1
3
2
0
1
6
-		 2
0
1
6
2
0
2
0
-
C
i
t
t
u
n
g		 2
4
0
8		 3
0
1
4		 3
9
6
5		 7
8
,		 7
1
,
l
d
d
W
i
B
i
e
n
g
a
n
r
a
z
n
g		 1
2
4
9		 1
6
0
5		 2
2
3
1		 8
7
,		 8
6
,
f
d
h
S
O
t
t
t
t
u
r
a
c
e
r
e
a
m
e
n
a
n
e
r		 5
0		 6
3		 8
6		 8
3
,		 8
1
,
l
T
t
o
a		 3
7
0
7		 4
6
8
2		 6
2
8
2		 8
1
,		 7
6
,

El.En. Group

Group Overview

High –Tech laser photonics Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 30 years stratification of multidisciplinary experience

FY 2014: Consolidated Revenues of €180 mln, up 14% YoY H1 2015: Consolidated Revenues of €107 mln, up 33% YoY

975 employees

Global positioning

El.En. Group

Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications

Industrial

Combine High tech laser source development with flexible production facilities in high growth areas

Medical

Technological and clinical innovation improving performance andbroadening the application scope of our laser systems

Maximize market penetration by multi brand approach

Open new market segments by developing innovative applications

Leverage worldwide distribution with multi brand approach

Consolidated Revenuesand EBIT

R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction

Broadening Mona Lisa Touch Clinical studiesCentral role of PHOTOBIOLABClinical studies on cutaneous ulcers New Pico second laser platform New dermatological applicationsPatents developmentIncreased power of RF laser sourcesInnovative beam delivery and focusing systems

H1 -2015 Financial Results

ConsolidatedP&L

/
E
0
0
0
r
o
u		 /
/
3
0
0
6
1
4		 /
/
3
0
0
6
1
5		 %
V
a
r.
R
e
v
e
n
u
e
s		 8
0
3
9
8		 1
0
0
0
%
,		 1
0
6
8
8
4		 1
0
0
0
%
,		 3
2
9
%
,
i
G
r
o
s
s
m
a
r
g
n		 3
8
0
8
5		 3
%
4
7
,		 4
8
0
7
7		 0
%
4
5
,		 2
6
3
%
,
E
B
I
T
D
A		 0
7
4
4		 %
8
8
,		 2
2
9
1
5		 %
1
1
7
,		 %
7
7
9
,
I
E
B
T
*
(
)		 6
4
8
4		 8
%
1
,		 1
0
3
4
7		 9
%
7
,		 6
0
0
%
,
P
I
t
(


)
r
e
a
x
n
c
o
m
e		 3
9
1
1
5		 %
1
4
1
,		 6
9
1
1
4		 %
1
0
9
,		 %
3
0
,
i
N
t
(


)
e
n
c
o
m
e		 8
4
9
2		 0
6
%
1
,		 7
6
2
3		 %
7
1
,		 0
2
%
1
-
,
h
N
I
t
e
n
c
o
m
e
p
e
r
s
a
r
e		 1
7
7
,		 8
1
5
,		 0
6
%
1
-
,
/
/
3
1
1
2
1
4		 /
/
3
0
0
6
1
5
f
l
i
i
i
i
N
t
t
(


*
)
e
n
a
n
c
a
p
o
s
o
n		 6
4
7
1
1		 2
8
4
7
5

(*) 2014 Non recurring: +1,5 mln of euros. 2014 EBIT% w/o non recurring: 6,2% and var% 15/14 adj.: +107%

(**) 2014 Total one time and non recurring: +6,0mln of euros on pretax income

+5,4 mln on net income and var% 15/14 adj.: +148%

(***) 2015 Nfp w/o 9,5 mln of euros as m/l temporay financial investments

ConsolidatedBS

/
0
0
0
E
u
r
o		 /
/
3
1
1
2
1
4		 /
/
3
0
0
6
1
5		 %
V
a
r.
6
1
7
7
5		 8
7
0
0
4		 %
4
1
4
9
0
1
5		 6
2
0
3
6		 2
%
5
4
7
1
1
6		 2
4
7
5
8		 %
4
7
-
7
8
5
6		 7
9
9
1		 %
2
i
N
E
t
t
e
q
u
y		 1
5
0
5
3
6		 1
6
5
8
0
7		 %
1
0
1
0
3
4
2
0		 1
4
1
0
4
8		 3
6
%
6
2
%		 8
%
5
R
O
C
E
6
%		 %
7
C
a
p
e
x		 2
3
8
1		 3
9
0
8

Total non current assetsNet Working CapitalNet financial positionLong term liabilitiesNet capital employed

Net Working Capital on sales(EBIT/Net capital employed)

2015 Guidance

2015 forecast

Sales: 200 mln +11%

EBIT: % on Sales and amount to improve on 2014

NEW

Sales: >210 mln +17%

EBIT: >20 mln

El.En. Stock, Multiples & Comparables

Euro

El.En. Multiples

*
k
h
l
d
's
i
h
S
E
t
t
o
c
o
e
r
q
p
e
r
s
a
r
e
u
y		 3
2
/
k
l
d
i
j.
P
B
V
A
r
c
e
o
o
a
u
e		 1,
2
8
/
(
)
8
%
E
V
E
B
I
T
5
E
B
I
T		 7,
4
5
/
(
)
l
l
E
V
S
8
5
%
S
a
e
s
a
e
s		 0,
7
2
l.
k
E
E
M
C
t
n.
a
r
e
a
p.		 1
9
7,
4
@
€
4
0,
9
2
f
l
i
i
i
i
N
t
t
e
n
a
n
c
a
p
o
s
o
n		 /
/
2
8
@
3
0
0
6
4,
1
5
/
l
l
i
i
i
F
t
t
t
n
a
n
c
a
n
v
e
s
m
e
n
s
m
e
r
m		 /
/
@
9,
5
3
0
0
6
1
5
k
l
f
h
1,
0
C
M
t
a
r
e
a
e
o
m
m
n
o
s
r
e
s
a
r
e
s
v
u
y
u		 \$
3
1,
@
3
8
3
7
5,
/
(
d
)
U
1,
1
3
E
r
o
s
u
=
l
i
E
V
t
n
e
r
p
r
s
e
a
u
e		 1
3
1,
5
k
h
l
d
's
i
f
i
i
i
S
E
t
t
t
t
o
c
o
e
r
q
u
y
n
e
o
m
n
o
r
e
s,
*
(
)
h
h
k
l
i
C
t
t
t
n
o
s
r
e
s
a
r
e
s
a
m
a
r
e
a
e
w
y
u
v
u		 1
5
4,
7

El.En. Comparables

ic
Pr
e		 Re
ve
nu
e		 %
Va
r.		 E
B
I
T		 %
E
B
I
T		 C
M
K.
a
p.		 E
V		 /
le
S
E
V
a
s		 /
E
V
E
B
I
T		 /
k
P
Bo
o
J
3
0,
2
0
1
5
u
n
e		 Re
ve
nu
e		 (
*)		 (
*)		 lu
Va
e
/
d
l
h
M
i
A
i
t
t
e
c
a
e
s
e
c
Sy
ne
ro
n		 \$
8,
9
4		 \$
1
3
6.
8
8
4		 1
3
%		 \$
(
)
1.
4
0
4		 -1
%		 \$
3
2
5.
0
9
0		 \$
2
3
2.
8
0
7		 0,
8
5		 n.
a.		 1,
4
5
l
iq
Ze
t		 \$
3
8
5,
1		 \$
9
8
9
1
1
5.		 9
%
4		 \$
(
)
4
1		 0
%		 \$
3
9
0.
0
0
0
1.		 \$
3
6
3
1.
4
1.
1		 8
5,
7		 n.
a.		 8,
2
1
7
Cu
t
e
ra		 \$
1
5,
1
0		 \$
4
1.
6
3
4		 2
3
%		 \$
(
)
5.
5
3
4		 -1
3
%		 \$
2
1
3.
4
7
0		 \$
1
4
7.
1
6
5		 1,
7
7		 n.
a.		 3,
1
5
la
B
io
s
e		 \$
1,
4
9		 \$
2
2.
7
2
4		 %
5		 \$
(
)
1
2.
2
8
8		 %
-5
4		 \$
8
6.
7
0
0		 \$
6
6.
8
1
6		 1,
4
7		 n.
a.		 2,
7
9
Cy
no
su
re		 \$
3
5,
8
3		 \$
1
5
8.
6
0
6		 1
8
%		 \$
9.
6
9
4		 6
%		 \$
8
1
0.
7
0
0		 \$
6
8
2.
5
7
5		 2,
1
5		 3
5,
2
1		 2,
1
1
d
i
l
I
t
n
u
s
r
a
ho
I
P
G
P
ic
C
t
o
n
s
o.		 \$
8
2,
8
4		 \$
4
3
4.
0
9
8		 2
0
%		 \$
1
6
9.
4
6
5		 3
9
%		 \$
4.
3
7
0.
0
0
0		 \$
3.
8
0
0.
0
9
0		 4,
3
8		 1
1,
2
1		 3,
7
6
f
Ro
in
-S
in
a
r		 \$
2
5,
2
5		 \$
2
5
5.
2
6
3		 %
-3		 \$
2
7.
4
1
7		 %
1
1		 \$
7
1
1.
5
9
0		 \$
5
4
4.
5
4
1		 1,
0
7		 9,
9
3		 1,
3
4
du
im
In
ie
Pr
t
a
s
r		 €
1
4,
4
1		 €
1
9
4
0
7
5.		 1
4
%		 €
8.
2
1
9		 %
5		 €
1
0.
8
6
0
5		 €
2
3
2
5
7.
5		 0,
3
7		 1
6
5,
7		 1,
2
0
l.
(
)
E
En
1		 €
4
0,
9
2		 €
1
0
6.
8
8
4		 3
3
%		 €
1
0.
3
7
4		 1
0
%		 €
1
9
7.
4
1
3		 €
1
3
1.
4
6
6		 0,
7
2		 7,
4
5		 1,
2
8
(
)
d
l
l
1
E
V
ip
ie
t
a
n
m
u
s
a
s		 fo
l
io
i
r p
re
v
u
s
s		 d
e
(
*)
d
b
Re
E
i
t
ve
nu
e
a
n
a
nn		 l
d
ize
a
u

El.En. SPA

Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI Financial CommunicationTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]

POLYTEMS HIR SRL

Veronica ADRIANIPress officeTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]

More from El.En.

Regulatory Filings 2025
Dec 22
Transaction in Own Shares 2025
Dec 22
Share Issue/Capital Change 2025
Dec 22
Transaction in Own Shares 2025
Dec 3
Investor Presentation 2025
Dec 3
Report Publication Announcement 2025
Dec 3
Report Publication Announcement 2025
Dec 3
Registration Form 2025
Nov 28
Share Issue/Capital Change 2025
Nov 28
Share Issue/Capital Change 2025
Nov 28
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.